Browse by category

A systematic review and meta-analysis that evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or overweight or obesity, has found that the drugs probably have little or no effect on risk for thyroid, pancreatic, breast, or kidney cancer and may have little or no effect on other obesity-related cancers. However, the researchers from Harvard Medical School stated the certainty

A large observational study of more than 170,000 patients with diabetes and obesity in the US has found that glucagon-like peptide-1...

Waist circumference (WC) is a stronger risk marker than BMI for developing obesity-related cancers in men, but not women, according to a...

Research to be presented at this year’s European Congress on Obesity 2025 (Malaga, Spain) shows that a new diagnosis of type 2 diabetes...

First generation weight-loss medications like liraglutide and exenatide appear to show anti-cancer benefits beyond weight loss. Indeed,...

A team of researchers at the University of Connecticut have developed a novel tool to help understand consumer behaviour at the county...

Obesity-related cancer rates in China were rising at an alarming 3.6% every year between 2007 and 2021, while non-obesity-related cancers...

The preventive association between bariatric surgery and obesity-related cancer and cardiovascular disease may be limited to younger...

Metabolically healthy and unhealthy 'forms' of obesity are associated with an increased risk of various obesity-related cancers, with the...

People who are metabolically unhealthy are at a higher risk of certain forms of cancer, regardless of their body weight, according to a...